Global Schizophrenia Drugs (Orals & Injectables) Market: Insights, Trends and Forecast (2019-2023)
The fastest growing regional market is Americas owing to continuous advancement in the second & third generation anti-psychotic drugs, increasing schizophrenia population and development.
By: Koncept Analytics
On the basis of mode of administration, schizophrenia market has been segmented into long acting injections and oral. Amongst them, owing to effective long-term relapse prevention, increased patient compliance, ease of administration and reduced hospitalization rates, long acting injections are widely used for managing or treating schizophrenia patients.
The fastest growing regional market is Americas owing to continuous advancement in the second & third generation anti-psychotic drugs, increasing schizophrenia population and development of economical long acting drugs by local manufacturers in US and Canada. The US is the largest market and is already well-penetrated at developed market levels.
Scope of the report:
• The report provides a comprehensive analysis of the global schizophrenia market, segmented on the basis of mode of administration i.e. oral & long acting injections, by therapeutic class i.e. second generation & third generation anti-psychotics and drug type i.e. Invega Sustenna, Latuda, Arsitada & Rexulti.
• The major regional markets (Americas, Europe and Asia-Pacific)
• The market dynamics such as growth drivers, market trends and challenges are analysed in-depth.
• The competitive landscape of the market, along with the company profiles of leading players (Allergan Plc, Johnson & Johnson, Otsuka Holdings Co., Ltd., Sumitomo Chemical Co., Ltd., Alkermes Plc and Acadia Pharmaceuticals Inc.) are also presented in detail.
For more Information:
(Business Development Manager)
FFCS-36, Ansal Plaza
U.P - 201010
Mail ID – firstname.lastname@example.org